GlassScriptPhysician profile
Miles Mahan
NPI 1164478061
$329.51
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $63.11 · 2021: $37.21 · 2022: $34.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $114.22 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.38 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $50.05 | 2019 | |
| Lupin INC. | $31.24 | 2019 | |
| Exeltis, USA INC. | $25.12 | 2019-2020 | |
| Aspira Women'S Health INC | $17.62 | 2020 | |
| Mission Pharmacal Company | $16.84 | 2019 | |
| Duchesnay USA Incorporated | $14.04 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miles Mahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.